What Is OSPHOS?
- OSPHOS is an injectable bisphosphonate, containing the active ingredient clodronate disodium at a concentration of 51 mg/mL, manufactured by Dechra. It is licensed for the control of clinical signs associated with navicular syndrome — specifically, forelimb lameness linked to bone-resorptive processes affecting the distal sesamoid (navicular) bone — in adult horses aged 4 years and older.
- Unlike hyaluronate-based joint injections such as Halo or HY-50 Vet, which work by restoring joint lubrication, OSPHOS belongs to a different drug class entirely. Bisphosphonates work by regulating bone resorption — the process by which bone tissue is broken down — helping to slow the bone changes associated with navicular disease.
What Is OSPHOS Used For?
- OSPHOS is indicated specifically for horses showing clinical forelimb lameness associated with navicular syndrome. It is administered as a course of intramuscular injections under direct veterinary supervision, forming part of a broader lameness management plan alongside farriery, exercise management, and other veterinary care as advised by the treating vet.
Dosage and Administration
- Route: Intramuscular (IM) injection only
- Dose: 1.53 mg clodronic acid per kg of body weight, equivalent to 3 mL of product per 100 kg body weight
- Administration: The total dose should be divided evenly across 2–3 separate injection sites
- Maximum dose: 765 mg clodronic acid per horse — one 15 mL vial covers a horse over 500 kg
- Do not exceed the recommended dose
Important Safety Information
OSPHOS carries specific safety considerations that every prescribing veterinarian and horse owner should be aware of:
- For intramuscular use in horses only — not licensed for use in horses intended for human consumption
- Do not use in horses with impaired renal function or a history of renal disease
- NSAIDs must not be used concurrently with OSPHOS, as combined use may increase the risk of renal toxicity and acute kidney failure
- Not recommended in horses with conditions affecting renal function or mineral/electrolyte balance
- Safety has not been evaluated in horses under 4 years of age or in breeding horses
- Must not be used in pregnant or lactating mares, or mares intended for breeding
- Reported side effects include signs of discomfort, nervousness, and colic; less commonly reported effects include renal failure, changes in thirst/urination, reduced appetite, lethargy, elevated blood calcium, behavioral changes, muscle tremor, injection site reactions, and — in rare cases — fracture
Always consult the full prescribing information and discuss your horse’s health history with your veterinarian before starting treatment.
Prescription Requirement
- OSPHOS is available strictly by veterinary prescription (POM-V) and must only be administered by, or under the direct supervision of, a licensed veterinarian who has assessed the horse’s suitability for treatment.
Why Choose Wadi Alhgn Veterinary Medicines for OSPHOS
- At Wadi Alhgn Veterinary Medicines, OSPHOS is sourced exclusively through authentic, verified Dechra supply channels, with correct cold-chain handling and full traceability. Under the guidance of Founder & CEO Dr. Sameh Ali, our team supports licensed veterinarians across the region with genuine navicular disease management options they can trust.
Request OSPHOS for Your Clinic.
Reviews
There are no reviews yet.